1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Digital Health and Artificial Intelligence Tools for Biomedical and Behavioral Research: Validity and Utility" is currently closed and not accepting applications.
Digital Health and Artificial Intelligence Tools for Biomedical and Behavioral Research: Validity and Utility is sponsored by National Institute on Drug Abuse (NIDA) - NIH, National Institute on Aging (NIA) - NIH. This topic encourages the evaluation of the validity and clinical utility of digital health and artificial intelligence (AI) tools and technologies in biomedical and behavioral research.
For NIDA, this includes validating digital health tools and AI/ML technologies to prevent, diagnose, and treat substance use disorders (SUDs). For NIA, this includes AI/ML analysis of multimodal data to study aging biology, function, behavior, longevity, and biomarkers or therapeutic targets. SBIR/STTR applications are encouraged when market need is defined and the product has strong commercialization potential.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses. Confirm the full requirements in the official notice before applying.
The published deadline was June 26, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Digital Health and Artificial Intelligence Tools for Biomedical and Behavioral Research: Validity and Utility is funded by National Institute on Drug Abuse (NIDA) - NIH, National Institute on Aging (NIA) - NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read article